{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:17:59Z","timestamp":1780489079452,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006529","name":"Race and Difference Initiative, Emory University","doi-asserted-by":"publisher","award":["29 PFE \/ 30.12.2021"],"award-info":[{"award-number":["29 PFE \/ 30.12.2021"]}],"id":[{"id":"10.13039\/100006529","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018987","name":"Ministerul Cercet\u0103rii, Inov\u0103rii \u015fi Digitaliz\u0103rii","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.biopha.2022.113077","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T19:34:57Z","timestamp":1651865697000},"page":"113077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat"],"prefix":"10.1016","volume":"150","author":[{"given":"Ruxandra-Cristina","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Streinu-Cercel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia Cristina","family":"Moleriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Gabriela","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2022.113077_bib1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/09540121.2012.712667","article-title":"The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis","volume":"25","author":"Al-Dakkak","year":"2013","journal-title":"AIDS Care"},{"issue":"3","key":"10.1016\/j.biopha.2022.113077_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059337","article-title":"Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011","volume":"8","author":"Bontell","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.biopha.2022.113077_bib3","first-page":"2197","article-title":"Evolution of the K65R, K103N and M184V\/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010","volume":"68","author":"Charpentier","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2022.113077_bib4","unstructured":"Comisia Na\u021bional\u0103 de Lupta Anti-SIDA - Date Statistice, 2020. (2020). Retrieved 2021, March 03 from http:\/\/cnlas.ro\/com_jce\/date-statistice.html."},{"issue":"5","key":"10.1016\/j.biopha.2022.113077_bib5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/jac\/dkt517","article-title":"Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group","volume":"69","author":"Curran","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2022.113077_bib6","first-page":"64","article-title":"Mechanisms of resistance to antiretroviral drugs--clinical implications","volume":"4","author":"de Mendoza","year":"2002","journal-title":"AIDS Rev."},{"issue":"1","key":"10.1016\/j.biopha.2022.113077_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-013-0159-3","article-title":"Darunavir: a review of its use in the management of HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2022.113077_bib8","doi-asserted-by":"crossref","unstructured":"Deeks, S.G. (2000, Jun). Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis, 30 Suppl 2, S177\u2013184. https:\/\/doi.org\/10.1086\/313855.","DOI":"10.1086\/313855"},{"key":"10.1016\/j.biopha.2022.113077_bib9","doi-asserted-by":"crossref","unstructured":"Eron, J.J., Jr. (2000, Jun). HIV-1 protease inhibitors. Clin Infect Dis, 30 Suppl 2, S160\u2013170. https:\/\/doi.org\/10.1086\/313853.","DOI":"10.1086\/313853"},{"key":"10.1016\/j.biopha.2022.113077_bib10","unstructured":"European Clinical AIDS Society. (2020). Retrieved January 21, 2022 from https:\/\/www.eacsociety.org\/files\/guidelines-10.1_5.pdf <p class=\"MsoNormal\">"},{"key":"10.1016\/j.biopha.2022.113077_bib11","unstructured":"European Medicines Agency, 2015. (2015). Retrieved 2021, March 11 from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-clinical-practice-e6r2\u20134-step-2b_en.pdf."},{"issue":"9519","key":"10.1016\/j.biopha.2022.113077_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(06)68580-2","article-title":"Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment","volume":"367","author":"Ferradini","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2022.113077_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/aid.2010.0072","article-title":"The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors","volume":"27","author":"Flor-Parra","year":"2011","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"14","key":"10.1016\/j.biopha.2022.113077_bib14","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/00002030-200209270-00017","article-title":"Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy","volume":"16","author":"Greub","year":"2002","journal-title":"Aids"},{"key":"10.1016\/j.biopha.2022.113077_bib15","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, 2021. (2021). Retrieved 2021, March 17 from https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"10.1016\/j.biopha.2022.113077_bib16","unstructured":"HIV Care Continuum . (2021). Retrieved June 22, 2021 from https:\/\/www.hiv.gov\/federal-response\/policies-issues\/hiv-aids-care-continuum."},{"key":"10.1016\/j.biopha.2022.113077_bib17","doi-asserted-by":"crossref","unstructured":"Hosseinipour, M.C., van Oosterhout, J.J., Weigel, R., Phiri, S., Kamwendo, D., Parkin, N., Fiscus, S.A., Nelson, J.A., Eron, J.J., & Kumwenda, J. (2009, Jun 1). The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. Aids, 23(9), 1127\u20131134. https:\/\/doi.org\/10.1097\/QAD.0b013e32832ac34e.","DOI":"10.1097\/QAD.0b013e32832ac34e"},{"issue":"4","key":"10.1016\/j.biopha.2022.113077_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.biopha.2022.113077_bib19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/jcph.290","article-title":"Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers","volume":"54","author":"Kakuda","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113077_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3851\/IMP2814","article-title":"Bioequivalence of a darunavir\/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers","volume":"19","author":"Kakuda","year":"2014","journal-title":"Antivir. Ther."},{"issue":"16","key":"10.1016\/j.biopha.2022.113077_bib21","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1128\/JVI.75.16.7462-7469.2001","article-title":"Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients","volume":"75","author":"Kempf","year":"2001","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113077_bib22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1086\/597779","volume":"48","author":"Kouanfack","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2022.113077_bib23","first-page":"851","article-title":"[The efficacy of antiviral therapy and drug resistance analysis among HIV\/AIDS patients with heroin addiction in Guangxi Zhuang Autonomous Region]","volume":"48","author":"Liang","year":"2014","journal-title":"Zhonghua Yu Fang. Yi Xue Za Zhi"},{"issue":"11","key":"10.1016\/j.biopha.2022.113077_bib24","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/QAD.0b013e3283611931","article-title":"Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China","volume":"27","author":"Liao","year":"2013","journal-title":"Aids"},{"issue":"3","key":"10.1016\/j.biopha.2022.113077_bib25","first-page":"168","article-title":"Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment","volume":"14","author":"Llibre","year":"2012","journal-title":"AIDS Rev."},{"issue":"4","key":"10.1016\/j.biopha.2022.113077_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jphs.2018.11.016","article-title":"Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy","volume":"139","author":"Luo","year":"2019","journal-title":"J. Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2022.113077_bib27","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1128\/JVI.72.9.7632-7637.1998","article-title":"Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients","volume":"72","author":"Mammano","year":"1998","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113077_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030313","article-title":"Management of antiretroviral therapy with boosted protease inhibitors-darunavir\/ritonavir or darunavir\/cobicistat","volume":"9","author":"Marin","year":"2021","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.biopha.2022.113077_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080987","article-title":"Comparison of tolerability and impact on metabolic profiles of antiretroviral regimens containing darunavir\/ritonavir or darunavir\/cobicistat in Romanian HIV infected patients","volume":"9","author":"Marin","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.biopha.2022.113077_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","article-title":"Darunavir: a review of its use in the management of HIV infection in adults","volume":"69","author":"McKeage","year":"2009","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2022.113077_bib31","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1128\/AAC.44.12.3465-3472.2000","article-title":"Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2\u2032-deoxynucleoside triphosphates","volume":"44","author":"Meyer","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 3","key":"10.1016\/j.biopha.2022.113077_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350100603S03","article-title":"Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure","volume":"6","author":"Miller","year":"2001","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.113077_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350100600205","article-title":"Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication","volume":"6","author":"Naeger","year":"2001","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.113077_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/sextrans-2020-054551","article-title":"Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries","volume":"97","author":"Okoli","year":"2021","journal-title":"Sex. Transm. Infect."},{"issue":"12","key":"10.1016\/j.biopha.2022.113077_bib35","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"Aids"},{"issue":"4","key":"10.1016\/j.biopha.2022.113077_bib36","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"20","key":"10.1016\/j.biopha.2022.113077_bib37","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.286.20.2560","article-title":"HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load","volume":"286","author":"Phillips","year":"2001","journal-title":"Jama"},{"issue":"10","key":"10.1016\/j.biopha.2022.113077_bib38","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/aid.2007.0275","article-title":"Effect of baseline viral susceptibility on response to darunavir\/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2","volume":"24","author":"Pozniak","year":"2008","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"2","key":"10.1016\/j.biopha.2022.113077_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/135965350901400210","article-title":"Risk factors for loss of virological suppression in patients receiving lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"14","author":"Pulido","year":"2009","journal-title":"Antivir. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2022.113077_bib40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.aids.0000131310.52526.c7","article-title":"The prevalence of antiretroviral drug resistance in the United States","volume":"18","author":"Richman","year":"2004","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.biopha.2022.113077_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jmv.20395","article-title":"Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients","volume":"77","author":"Rodes","year":"2005","journal-title":"J. Med Virol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113077_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/aid.2018.0178","article-title":"Simplification of antiretroviral treatment from darunavir\/ritonavir monotherapy to darunavir\/cobicistat monotherapy: effectiveness and safety in routine clinical practice","volume":"35","author":"Santos","year":"2019","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"1","key":"10.1016\/j.biopha.2022.113077_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/infdis\/172.1.70","article-title":"Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team","volume":"172","author":"Shafer","year":"1995","journal-title":"J. Infect. Dis."},{"issue":"15","key":"10.1016\/j.biopha.2022.113077_bib44","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/00002030-200210180-00008","article-title":"Prevalence and clinical correlates of HIV viremia (\u2019blips\u2019) in patients with previous suppression below the limits of quantification","volume":"16","author":"Sklar","year":"2002","journal-title":"Aids"},{"issue":"4\u20135","key":"10.1016\/j.biopha.2022.113077_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10877-005-0673-2","article-title":"A Grid-based HIV expert system","volume":"19","author":"Sloot","year":"2005","journal-title":"J. Clin. Monit. Comput."},{"key":"10.1016\/j.biopha.2022.113077_bib46","unstructured":"Stanford University HIV drug resistance database. (2020). Retrieved June 12, 2021 from https:\/\/hivdb.stanford.edu\/page\/who-sdrm-list\/."},{"issue":"4","key":"10.1016\/j.biopha.2022.113077_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.18683\/germs.2019.1178","article-title":"Consensus statement on the assessment of comorbidities in people living with HIV in Romania","volume":"9","author":"Streinu-Cercel","year":"2019","journal-title":"Germs"},{"key":"10.1016\/j.biopha.2022.113077_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-6405-11-39","article-title":"Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial","volume":"11","author":"Tashima","year":"2014","journal-title":"AIDS Res. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2022.113077_bib49","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00006454-200207000-00015","article-title":"Human immunodeficiency virus drug susceptibility and resistance testing","volume":"21","author":"Tobin","year":"2002","journal-title":"Pedia Infect. Dis. J."},{"key":"10.1016\/j.biopha.2022.113077_bib50","unstructured":"van Maarseveen, N., & Boucher, C. (2006). Resistance to protease inhibitors. In A. M. Geretti (Ed.), Antiretroviral Resistance in Clinical Practice. Mediscript Copyright \u00a9 2006, Mediscript."},{"issue":"8","key":"10.1016\/j.biopha.2022.113077_bib51","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.4155\/fmc.15.44","article-title":"Highly resistant HIV-1 proteases and strategies for their inhibition","volume":"7","author":"Weber","year":"2015","journal-title":"Fut. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2022.113077_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance","volume":"85","author":"Wensing","year":"2010","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.biopha.2022.113077_bib53","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/AAC.41.4.757","article-title":"Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years","volume":"41","author":"Winters","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.113077_bib54","unstructured":"World Medical Association, 2018. (2018). Retrieved 2021, February 26 from https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"issue":"3","key":"10.1016\/j.biopha.2022.113077_bib55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.bmcl.2013.12.057","article-title":"Structure\u2013activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2\/P3 region and discovery of cobicistat (GS-9350)","volume":"24","author":"Xu","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2022.113077_bib56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer","volume":"1","author":"Xu","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2022.113077_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5582\/bst.2015.01107","article-title":"The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China","volume":"9","author":"Zhang","year":"2015","journal-title":"Biosci. Trends"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:50:12Z","timestamp":1780487412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222004668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":57,"alternative-id":["S0753332222004668"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113077","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113077"}}